FCGR3A and neoplasm: FT596 employs three anti-tumor strategies: (1) a proprietary CD19-targeting CAR; (2) a high-affinity, non-cleavable CD16 Fc receptor that facilitates tumor targeting and enhances ADCC when paired with a therapeutic mAb; and (3) an IL-15/IL-15 receptor fusion that promotes cytokine-autonomous persistence.